45 related articles for article (PubMed ID: 22178553)
21. A stereoselective approach to peptidomimetic BACE1 inhibitors.
Butini S; Gabellieri E; Brindisi M; Giovani S; Maramai S; Kshirsagar G; Guarino E; Brogi S; La Pietra V; Giustiniano M; Marinelli L; Novellino E; Campiani G; Cappelli A; Gemma S
Eur J Med Chem; 2013; 70():233-47. PubMed ID: 24158015
[TBL] [Abstract][Full Text] [Related]
22. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design.
Hamada Y; Tagad HD; Nishimura Y; Ishiura S; Kiso Y
Bioorg Med Chem Lett; 2012 Jan; 22(2):1130-5. PubMed ID: 22178553
[TBL] [Abstract][Full Text] [Related]
23. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
[TBL] [Abstract][Full Text] [Related]
24. The evolution of amidine-based brain penetrant BACE1 inhibitors.
Oehlrich D; Prokopcova H; Gijsen HJ
Bioorg Med Chem Lett; 2014 May; 24(9):2033-45. PubMed ID: 24704031
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011).
Probst G; Xu YZ
Expert Opin Ther Pat; 2012 May; 22(5):511-40. PubMed ID: 22512789
[TBL] [Abstract][Full Text] [Related]
26. Progress toward a practical BACE-1 inhibitor.
Hills ID; Vacca JP
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):383-91. PubMed ID: 17659479
[TBL] [Abstract][Full Text] [Related]
27. Advances in the identification of β-secretase inhibitors.
Hamada Y; Kiso Y
Expert Opin Drug Discov; 2013 Jun; 8(6):709-31. PubMed ID: 23565721
[TBL] [Abstract][Full Text] [Related]
28. Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story.
Stamford A; Strickland C
Curr Opin Chem Biol; 2013 Jun; 17(3):320-8. PubMed ID: 23683349
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease.
Yuan J; Venkatraman S; Zheng Y; McKeever BM; Dillard LW; Singh SB
J Med Chem; 2013 Jun; 56(11):4156-80. PubMed ID: 23509904
[TBL] [Abstract][Full Text] [Related]
30. Structure-Based Survey of the Binding Modes of BACE1 Inhibitors.
Hu H; Chen Z; Xu X; Xu Y
ACS Chem Neurosci; 2019 Feb; 10(2):880-889. PubMed ID: 30540177
[TBL] [Abstract][Full Text] [Related]
31. The potential for BACE1 inhibitors in the treatment of Alzheimer's disease.
Hussain I
IDrugs; 2004 Jul; 7(7):653-8. PubMed ID: 15243867
[TBL] [Abstract][Full Text] [Related]
32. N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as BACE1 inhibitors: a patent evaluation of WO2013041499.
Dessolin J
Expert Opin Ther Pat; 2014 Feb; 24(2):239-42. PubMed ID: 24219148
[TBL] [Abstract][Full Text] [Related]
33. Design of potent aspartic protease inhibitors to treat various diseases.
Nguyen JT; Hamada Y; Kimura T; Kiso Y
Arch Pharm (Weinheim); 2008 Sep; 341(9):523-35. PubMed ID: 18763714
[TBL] [Abstract][Full Text] [Related]
34. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
Silvestri R
Med Res Rev; 2009 Mar; 29(2):295-338. PubMed ID: 18651582
[TBL] [Abstract][Full Text] [Related]
35. Fragment-based designing for the generation of novel leads against BACE1.
Das S; Chakraborty S; Basu S
Cent Nerv Syst Agents Med Chem; 2015; 15(1):52-64. PubMed ID: 25625854
[TBL] [Abstract][Full Text] [Related]
36. BACE2 as a new diabetes target: a patent review (2010 - 2012).
Southan C
Expert Opin Ther Pat; 2013 May; 23(5):649-63. PubMed ID: 23506624
[TBL] [Abstract][Full Text] [Related]
37. Allosteric inhibition of BACE1 by an exosite-binding antibody.
Wang W; Liu Y; Lazarus RA
Curr Opin Struct Biol; 2013 Dec; 23(6):797-805. PubMed ID: 23998983
[TBL] [Abstract][Full Text] [Related]
38. New methods to explore marine resources for Alzheimer's therapeutics.
Williams P; Sorribas A; Liang Z
Curr Alzheimer Res; 2010 May; 7(3):210-3. PubMed ID: 20088803
[TBL] [Abstract][Full Text] [Related]
39. [Significance of quantum chemical interactions for medicinal science and design of β-secretase inhibitors].
Hamada Y
Yakugaku Zasshi; 2013; 133(10):1113-20. PubMed ID: 23832586
[TBL] [Abstract][Full Text] [Related]
40. Azapeptides as pharmacological agents.
Zega A
Curr Med Chem; 2005; 12(5):589-97. PubMed ID: 15777214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
